Protein– tag –
-
Precision Fermentation Powers All G’s Industrial-Scale Launch of Animal-Free Lactoferrin ‘LFX Apoprotein’ in US Market
AgFunderNews Australia Overview Australian biotechnology firm All G has commercially launched LFX Apoprotein, a novel animal-free, low-iron lactoferrin produced via precision fermentation, in the U.S. market. Currently scaled at a 60,000... -
ADM and Every Partner to Scale Precision Fermentation of Animal-Free Egg Protein ‘OvoPro’ by 550% at Clinton, Iowa Facility
Food Dive USA Overview ADM and Every are partnering to significantly scale the commercial production of OvoPro, an animal-free egg protein produced via precision fermentation, at ADM's Clinton, Iowa facility. This collaboration aims to b... -
FDA Approves Sanofi’s Subcutaneous Isatuximab (Sarclisa Escena) for Multiple Myeloma, Enhancing Patient Convenience
Drugs.com USA Overview The U.S. FDA has approved Sanofi's subcutaneous formulation, Sarclisa Escena (isatuximab-irfc), for multiple myeloma, significantly improving administration convenience for patients. This new formulation reduces tr... -
Lonza Achieves Strong H1 2026 Growth: CDMO Strategy Accelerates with Expanded ADC and High-Value Small Molecule Manufacturing
BioPharma BoardRoom Switzerland Overview Lonza CEO Wolfgang Wienand highlighted the company's strong growth in H1 2026, emphasizing the accelerating momentum of its CDMO strategy. Lonza expanded strategic long-term collaboration agreemen... -
Alcimed Analyzes Brain Drug Delivery Barriers and Breakthroughs: Receptor-Mediated Transcytosis and LIFU as Key Enablers
Alcimed France Overview Brain drug delivery is one of modern medicine's most complex challenges due to multiple physiological barriers, notably the blood-brain barrier (BBB), which severely restricts most therapeutic molecules from enter... -
Samsung Biologics Acquires PolyPeptide in All-Cash Offer: Accelerating Multi-Modality Strategy and Global Network Expansion
PR Newswire South Korea Overview Samsung Biologics announced an all-cash offer to acquire PolyPeptide, accelerating its multi-modality strategy and expanding its global manufacturing network across the U.S., Europe, and India. This acqui... -
FDA Approval a TPD Turning Point? Maria Soloveychik Cautions Single Molecule Success Doesn’t Guarantee All Targets
Drug Discovery Online USA Overview Maria Soloveychik acknowledges the FDA approval of a bivalent degrader as a crucial 'proof point' for the Targeted Protein Degradation (TPD) field but warns that this single molecular success does not n... -
Verseon Champions Physics-Based Molecular Design to Transcend AI’s Training Data in Drug Discovery
Endpoints News USA Overview Verseon asserts that physics-based molecular design can reach chemical spaces beyond the limitations of traditional screening and generative AI training data, opening untapped drug discovery realms. Their Deep... -
BeOne Medicines Invests $300M in New Jersey Manufacturing Expansion, Boosting Biologic, Small Molecule, and ADC Production
Fierce Pharma USA Overview BeOne Medicines announced a $300 million investment to significantly expand its manufacturing facility in New Jersey. The Hopewell campus, opened in 2024, will evolve into a fully integrated manufacturing hub, ... -
Breaking the Blood-Brain Barrier: Nanoparticles Chart New Course for Neurodegenerative Therapies
Dove Medical Press New Zealand Overview The blood-brain barrier (BBB) prevents over 98% of small-molecule drugs and nearly all biologics from entering the brain, posing a major challenge for neurological therapies. Nanoparticles (NPs) of...
